$77.91+60.90% · 3M
Moving avg
1W-0.22%
1M-0.22%
3M+60.90%
6M+68.78%
YTD+85.46%
1Y+119.40%
3Y+361.01%
5Y+520.80%
52-week range
$32.8990% of range$82.94
Company health
Value0/6
Growth3/6
Profitability4/6
Health5/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- High return on equity (1365%)
- Revenue compounding 105% a year
- Net cash on the balance sheet
Risks
- Richly valued at 75.0x earnings
Key statistics
Valuation
Market cap
$5.94B
Enterprise value
$5.94B
P/E ratio (TTM)
74.95x
P/S ratio (TTM)
7.27x
EV/EBITDA
53.04x
Per share & returns
EPS (TTM)
$1.04
Dividend yield
0.00%
Beta (1Y)
0.09
30-day change
-0.22%
Trading
Volume (24h)
430.05K
Previous close
$80.47
Shares outstanding
76.21M
About Kiniksa Pharmaceuticals International, plc
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Symbol
KNSA
Kiniksa Pharmaceuticals International, plc is a mid-cap healthcare company in the Medical - Pharmaceuticals industry.
Frequently asked questions
What is Kiniksa Pharmaceuticals International, plc's market cap?
Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalization of $5.94B.
What is Kiniksa Pharmaceuticals International, plc's P/E ratio?
Kiniksa Pharmaceuticals International, plc trades at a price-to-earnings (P/E) ratio of 74.95.
What exchange does KNSA trade on?
KNSA trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,148.20-0.98%
$1.08T cap
Johnson & JohnsonJNJ
$275.23-1.15%
$663.28B cap
AbbVie Inc.ABBV
$256.34-1.49%
$452.90B cap
Merck & Co., Inc.MRK
$150.34-1.31%
$371.31B cap
UnitedHealth Group IncorporatedUNH
$397.14-0.95%
$360.66B cap
Roche Holding AGSWX: ROP
CHF 357.00+0.14%
$350.91B cap
Novartis AGSWX: NOVN
CHF 129.58-1.33%
$304.13B cap
AstraZeneca PLCLON: AZN
£120.06-1.15%
$251.66B cap